[2026] Participation in NeuroFrontiers 2026 | The Future of Neurodegenerative Disease Diagnosis: A Glimpse from Singapore

Hello! This is Bredis Healthcare.

On June 2, Bredis Healthcare attended

NeuroFrontiers 2026: Biomarkers and Next-Generation Diagnostics in Neurological Disorders, held in Singapore!

Organized by Singapore’s A*STAR, this international workshop brought together experts, clinicians, scientists, and healthcare system leaders from Singapore, Asia, and the United States to discuss the present and future of biomarkers and next-generation diagnostic technologies in the field of neurodegenerative diseases.

I had the opportunity to hear firsthand just how urgent an issue neurodegenerative diseases—including dementia—are in rapidly aging Asia, and how blood, imaging, and digital biomarkers, along with multi-omics technologies, can be integrated into actual clinical practice.

Through networking, Bredis Healthcare introduced our neurology-focused biomarker analysis services utilizing the ultra-sensitive biomarker analyzer SIMOA and the multiplex analyzer NULISA, and engaged in active exchanges with global researchers and clinical experts.

It was a meaningful experience to witness firsthand the direction in which the diagnostic paradigm for neurodegenerative diseases is heading in Asia, as the region enters a super-aged society.

Moving forward, Bredis Healthcare will continue to align with global research trends to develop better diagnostic solutions.

We appreciate your continued support! 😊